Skip to main content

Multaq Side Effects

Generic name: dronedarone

Medically reviewed by Last updated on May 23, 2022.

Note: This document contains side effect information about dronedarone. Some of the dosage forms listed on this page may not apply to the brand name Multaq.


More frequent side effects include: abdominal pain, allergic dermatitis, diarrhea, eczema, nausea, pruritus, and skin rash. See below for a comprehensive list of adverse effects.

For the Consumer

Applies to dronedarone: oral tablets


  • Contraindicated in patients with NYHA class IV heart failure or symptomatic heart failure with recent decompensation requiring hospitalization.1 (See New-Onset or Worsening Heart Failure under Cautions.)

  • In the ANDROMEDA study in patients with severe heart failure requiring recent hospitalization or referral to a specialized heart failure clinic for worsening symptoms, dronedarone therapy was associated with a greater than twofold increase in mortality rate relative to placebo;1 4 do not use dronedarone in such patients.1

  • Contraindicated in patients with permanent atrial fibrillation; doubles the risk of cardiovascular death and heart failure in such patients.1 9 35 (See Warnings under Cautions.)


FDA approved a REMS for dronedarone to ensure that the benefits outweigh the risks. However, FDA later rescinded REMS requirements. See the FDA REMS page ([Web]).

Side effects include:

Early increases in Scr (increase of ≥10%), prolonged QTc interval, diarrhea, asthenic conditions, nausea, skin reactions (e.g., rash [generalized, macular, maculopapular, erythematous], pruritus, eczema, dermatitis, allergic dermatitis), abdominal pain, bradycardia, vomiting, dyspeptic manifestations. (See Prolongation of QT Interval and Increased Scr under Cautions.)

For Healthcare Professionals

Applies to dronedarone: oral tablet


Very common (10% or more): QT prolongation (28%)

Common (1% to 10%): Bradycardia

Very rare (less than 0.01%): New or worsening heart failure, atrial flutter with 1:1 atrioventricular conduction[Ref]


Frequency not reported: Hypokalemia and hypomagnesemia with potassium-depleting diuretics, serum creatinine increased 10% or more within 5 days after treatment initiation[Ref]


Common (1% to 10%): Diarrhea, nausea, abdominal pain, vomiting, dyspeptic symptoms

Frequency not reported: Dysgeusia, ageusia[Ref]


Common (1% to 10%): Rashes (generalized, macular, maculopapular, erythematous), pruritus, eczema, dermatitis, allergic dermatitis

Uncommon (0.1% to 1%): Photosensitivity[Ref]


Common (1% to 10%): Asthenia, fatigue[Ref]


Frequency not reported: Liver injury, including acute liver failure requiring transplant, serum hepatic enzymes, serum bilirubin increase


Frequency not reported: Dyspnea, nonproductive cough

Postmarketing reports: Interstitial lung disease including pneumonitis and pulmonary fibrosis


Common (1% to 10%): Urinary tract infection


Postmarketing reports: Vasculitis, including leukocytoclastic vasculitis


Postmarketing reports: Anaphylactic reactions including angioedema


Frequency not reported: Increased serum creatinine[Ref]


1. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0

2. "Product Information. Multaq (dronedarone)." sanofi-aventis (2009):

3. Cerner Multum, Inc. "Australian Product Information." O 0

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.